Dr. McBride on the Emergence of Biosimilars in Oncology

Video

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.

Biosimilars have been slowly evolving in the market, but McBride believes 2020 will be the “year of the biosimilar.” Many drug therapies have gotten approved; however, they are on hold due to patent litigation. Next year, McBride anticipates seeing a flood of therapeutic biosimilars in the oncology market.

There are many factors to consider with the emergence of biosimilars, including how biosimilars will interplay with care in community oncology—based facilities, academic facilities, and large integrated delivery systems, explains McBride. Additionally, a facility’s finances, formulary, and electronic health records need to be examined as biosimilars become more common. Patients and physicians should be educated about the use of biosimilars. Facilities need to consider how to enroll patients into programs for biosimilars and how financial advocates will address biosimilars, concludes McBride.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute